

Announcement Summary

Entity name

ARTRYA LIMITED

Announcement Type

New announcement

Date of this announcement

14/2/2025

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	Unlisted options exercise price \$1.095. Expiry 2 years from issue	2,054,795
AYA	ORDINARY FULLY PAID	20,547,946

Proposed +issue date

20/2/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

ARTRYA LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ACN

624005741

1.3 ASX issuer code

AYA

1.4 The announcement is

New announcement

1.5 Date of this announcement

14/2/2025

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition Date for determination Is the date estimated or ** Approval

+Security holder approval 2/4/2025 actual? received/condition met?

Estimated

Comments

Security holder approval is required for the issue of 13,749,448 ordinary shares under tranche 2 of the placement as well as for the issue of 2,054,795 lead manager options

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

Details of +securities proposed to be issued

ASX +security code and description

AYA: ORDINARY FULLY PAID

Number of +securities proposed to be issued

20,547,946

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

What is the issue price per +security?

AUD - Australian Dollar AUD 0.73000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?



Yes

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? New class

Will the proposed issue of this +security include an offer of attaching +securities? No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

Have you received confirmation from Will the entity be seeking quotation of the 'new' class of +securities on ASX? No

ASX +security code

+Security description

New class-code to be confirmed

Unlisted options exercise price \$1.095. Expiry 2 years from issue

+Security type

Options

Number of +securities proposed to be issued

2,054,795

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration? No

Please describe the consideration being provided for the +securities

Options issued to Petra Capital (or nominee) as lead manager for capital raise as announced to ASX on 14.2.2025

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

0.433000

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Options details

+Security currency **Exercise price Expiry date** AUD - Australian Dollar AUD 1.0950 8/4/2027



Details of the type of +security that will be issued if the option is exercised

AYA: ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

Each option will convert to 1 ordinary share fully paid

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Refer to ASX announcement dated 14.02.2025 for further detail

Part 7C - Timetable

7C.1 Proposed +issue date

20/2/2025

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

6,716,403

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?
Yes

7D.1c (i) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?

82,095

7D.1c (ii) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security holders would have been eligible to participate

The Company did not consider that a pro rata issue or a security purchase plan would deliver the funding achieved by the proposed placement in a timely manner

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Nο

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No



Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

Yes

7E.1a Who is the lead manager/broker?

Petra Capital

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

The lead manager will receive a 2% Offer Management Fee and a 4% Placement Fee and 2,054,795 options. The options are exercisable at \$1.095 and expire 2 years from the date of issue (which is estimated to be on or around 8 April 2025).

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Nil

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Proceeds will be applied to accelerate regulatory applications for Salix, customer implementation, clinical studies, R&D, regulatory costs & working capital and commencement of plaque study (SAPPHIRE)

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No

7F.2 Any other information the entity wishes to provide about the proposed issue

Tranche 1 - 6,798,498 placement shares to be issued on/around 20 February 2025 (indicative only)

Tranche 2 - 13,749,448 placement shares to be issued on/around 8 April 2025 (indicative only)

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)